FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900569084> ?p ?o ?g. }

• W2900569084 abstract "Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis. We evaluated aspirin use and breast cancer outcomes in relation to clinical characteristics as well as dose and duration of aspirin use.We used information from the Regional Breast Cancer Quality-of-Care Registries in three Swedish regions to identify 21,414 women diagnosed with a first stage I-III breast cancer between 1 April 2006 and 31 December 2012. The cohort was further linked to nationwide registers to retrieve information about dispensing low-dose aspirin before and after breast cancer diagnosis, comorbidity and causes of death. In a separate analysis, we investigated time to breast cancer death among 621 women with stage IV disease at diagnosis. Associations were evaluated using a multivariable Cox proportional hazards model.Among women with stage I-III breast cancer, 2660 (12.4%) used low-dose aspirin shortly before breast cancer diagnosis and 4091 (19.1%) were users during follow-up. Women were followed for a median of 3.8 years after diagnosis. There was no association between aspirin use and breast cancer-specific death in multivariable analyses (use before diagnosis: hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.77-1.12; use after diagnosis: HR 1.00, 95% CI 0.74-1.37). Similarly, aspirin use was not associated with risk of first recurrence/metastases in a subgroup of stage I-III breast cancer patients (HR 0.97, 95% CI 0.86-1.10). However, in analyses stratified by stage, an inverse association between low-dose aspirin use after diagnosis and breast cancer death was found for women with stage I tumors (HR 0.53, 95% CI 0.29-0.96). Among women with stage IV disease at diagnosis, aspirin use was not associated with time to breast cancer death (HR 0.91, 95% CI 0.67-1.23).In this large population-based cohort study there was no evidence that low-dose aspirin use before or after breast cancer diagnosis is associated with a reduced risk of adverse outcomes overall in breast cancer. However, a potential benefit was noted among women with stage I tumors, warranting further investigation." @default.
• W2900569084 created "2018-11-29" @default.
• W2900569084 creator A5012324741 @default.
• W2900569084 creator A5020784348 @default.
• W2900569084 creator A5027210595 @default.
• W2900569084 creator A5042856380 @default.
• W2900569084 creator A5045789618 @default.
• W2900569084 creator A5067832483 @default.
• W2900569084 creator A5072383576 @default.
• W2900569084 creator A5072581345 @default.
• W2900569084 date "2018-11-20" @default.
• W2900569084 modified "2023-10-06" @default.
• W2900569084 title "No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study" @default.
• W2900569084 cites W1605523334 @default.
• W2900569084 cites W1968171768 @default.
• W2900569084 cites W1974681954 @default.
• W2900569084 cites W2006818027 @default.
• W2900569084 cites W2007540402 @default.
• W2900569084 cites W2008308840 @default.
• W2900569084 cites W2044428399 @default.
• W2900569084 cites W2053237747 @default.
• W2900569084 cites W2067716914 @default.
• W2900569084 cites W2072063737 @default.
• W2900569084 cites W2093307943 @default.
• W2900569084 cites W2100411078 @default.
• W2900569084 cites W2114120215 @default.
• W2900569084 cites W2117427834 @default.
• W2900569084 cites W2124422993 @default.
• W2900569084 cites W2127735232 @default.
• W2900569084 cites W2131756199 @default.
• W2900569084 cites W2135069427 @default.
• W2900569084 cites W2135369095 @default.
• W2900569084 cites W2141761576 @default.
• W2900569084 cites W2151840649 @default.
• W2900569084 cites W2153181024 @default.
• W2900569084 cites W2160032256 @default.
• W2900569084 cites W2169885814 @default.
• W2900569084 cites W2178187880 @default.
• W2900569084 cites W2376159193 @default.
• W2900569084 cites W2535808455 @default.
• W2900569084 cites W2570618306 @default.
• W2900569084 cites W2579483702 @default.
• W2900569084 cites W2623703069 @default.
• W2900569084 doi "https://doi.org/10.1186/s13058-018-1065-0" @default.
• W2900569084 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6247765" @default.
• W2900569084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30458873" @default.
• W2900569084 hasPublicationYear "2018" @default.
• W2900569084 type Work @default.
• W2900569084 sameAs 2900569084 @default.
• W2900569084 citedByCount "27" @default.
• W2900569084 countsByYear W29005690842019 @default.
• W2900569084 countsByYear W29005690842020 @default.
• W2900569084 countsByYear W29005690842021 @default.
• W2900569084 countsByYear W29005690842022 @default.
• W2900569084 countsByYear W29005690842023 @default.
• W2900569084 crossrefType "journal-article" @default.
• W2900569084 hasAuthorship W2900569084A5012324741 @default.
• W2900569084 hasAuthorship W2900569084A5020784348 @default.
• W2900569084 hasAuthorship W2900569084A5027210595 @default.
• W2900569084 hasAuthorship W2900569084A5042856380 @default.
• W2900569084 hasAuthorship W2900569084A5045789618 @default.
• W2900569084 hasAuthorship W2900569084A5067832483 @default.
• W2900569084 hasAuthorship W2900569084A5072383576 @default.
• W2900569084 hasAuthorship W2900569084A5072581345 @default.
• W2900569084 hasBestOaLocation W29005690841 @default.
• W2900569084 hasConcept C121608353 @default.
• W2900569084 hasConcept C126322002 @default.
• W2900569084 hasConcept C143998085 @default.
• W2900569084 hasConcept C146357865 @default.
• W2900569084 hasConcept C151730666 @default.
• W2900569084 hasConcept C207103383 @default.
• W2900569084 hasConcept C2777628954 @default.
• W2900569084 hasConcept C2779159551 @default.
• W2900569084 hasConcept C2780140570 @default.
• W2900569084 hasConcept C2908647359 @default.
• W2900569084 hasConcept C44249647 @default.
• W2900569084 hasConcept C50382708 @default.
• W2900569084 hasConcept C530470458 @default.
• W2900569084 hasConcept C71924100 @default.
• W2900569084 hasConcept C86803240 @default.
• W2900569084 hasConcept C99454951 @default.
• W2900569084 hasConceptScore W2900569084C121608353 @default.
• W2900569084 hasConceptScore W2900569084C126322002 @default.
• W2900569084 hasConceptScore W2900569084C143998085 @default.
• W2900569084 hasConceptScore W2900569084C146357865 @default.
• W2900569084 hasConceptScore W2900569084C151730666 @default.
• W2900569084 hasConceptScore W2900569084C207103383 @default.
• W2900569084 hasConceptScore W2900569084C2777628954 @default.
• W2900569084 hasConceptScore W2900569084C2779159551 @default.
• W2900569084 hasConceptScore W2900569084C2780140570 @default.
• W2900569084 hasConceptScore W2900569084C2908647359 @default.
• W2900569084 hasConceptScore W2900569084C44249647 @default.
• W2900569084 hasConceptScore W2900569084C50382708 @default.
• W2900569084 hasConceptScore W2900569084C530470458 @default.
• W2900569084 hasConceptScore W2900569084C71924100 @default.
• W2900569084 hasConceptScore W2900569084C86803240 @default.
• W2900569084 hasConceptScore W2900569084C99454951 @default.
• W2900569084 hasFunder F4320322315 @default.
• W2900569084 hasIssue "1" @default.
• W2900569084 hasLocation W29005690841 @default.

• next